The global latent TB detection market is expected to reach US$ 1,684.86 million in 2027 from US$ 1,131.82 million in 2019. The market is estimated to grow with a CAGR of 5.2% from 2020-2027. The growth of the market is attributed to some key driving factors such as increasing prevalence of tuberculosis and government initiatives to promote tuberculosis detection. However, multidrug resistant tuberculosis (MDR-TB) is likely to hamper the growth of the market to a certain extent. The patient of latent TB does not show any kind of symptoms even when they are infected by M. tuberculosis. Also, the person suffering from latent TB does not spread the disease. Majorly, tuberculin skin test or TB blood test are recommended for the diagnosis of latent TB infection. Countries in Asia Pacific and South and Central America are emerging as attractive outsourcing locations for tuberculosis diagnosis.Asian economies, such as India, Indonesia, and China, are among the highest-affected countries with TB.
This drives the need for appropriate and advanced diagnostics for TB in these countries.According to the BMJ Medicine, Southeast Asia continues to battle TB as one of the most severe health challenges and does not have sufficient resources for latent TB detection, treatment, and medication facilities.
This provides market players with opportunities to build their sustainable bases in these regions and tap the unexplored opportunities. Low manufacturing and operating costs in China and India offer lucrative opportunities for the growth of diagnostic and therapeutic in the region.Recent growth in the biopharmaceutical industry in both China and India indicates positive future outlook for the market under study.
Moreover, the growing domestic market and its advancement of novel technologies are opening up new avenues for contract manufacturers and diagnostic test manufacturers for latent TB detection in APAC. Based on test, the latent TB detection market was segmented into tuberculin skin test (TST) and interferon gamma released assay (IGRA).In 2019, the tuberculin skin test (TST) segment accounted for the highest share in the market and is likely to retain its dominant share.
The TST results are obtained in around 48-72 hours.Reading the presence or absence as well as the amount of induration known as localized swelling does the reading of the test.
Although TST is a basic test performed in high volumes, the inaccuracy in detection is likely to hamper the growth of the segment during the coming years. On the other hand, the interferon gamma released assay (IGRA) is expected to witness fastest growth in the market owing to the accuracy obtained through these tests. The COVID-19 pandemic was first reported in December 2019 in Wuhan (China).The COVID-19 pandemic has threatened the national TB programs worldwide.
The WHO have also notified that pandemic is threatening to reverse global progress against tuberculosis. The COVID-19 response has affected multiple sectors of public health, recommended preventive screening, and clinical care around the globe. The Centers for Disease Control and Prevention (CDC), World Health Organization (WHO), European Union (EU), Organization for Economic Co-operation and Development, United States Agency for International Development (USAID), Ministry of Health and Prevention, US Food and Drug Administration (FDA), and Japan TB Surveillance System are a few of the prime secondary sources referred to while preparing this report.
Our reports have been used by over 10K customers, including:
The global organoids market is expected to reach US$ 3,420.40 million by 2027 from US$ 689.47 million in 2019. The market is estimated to grow at a CAGR of 22.1% from 2020 to 2027. Increasing demand for tumor modelling and biobanking, rising adoption of personalized drugs, and growing focus on developing alternatives for animal testing...
An organ-on-a-chip is a microfluidic cell culture device that contains continuously perfused chambers. This chip develops a narrow channel for the blood and airflow in organs, such as the lung, gut, liver, heart, and other organs. Such devices produce multiple levels of tissue and organ functionalities, which are not feasible using conventional...
The global immunofluorescence assays market is projected to reach USD 3.5 billion by 2026 from USD 2.6 billion in 2021, at a CAGR of 6.0% during the forecast period. The growth in this market is primarily attributed to the increasing prevalence of chronic diseases and rising R&D spending & healthcare expenditure. Emerging markets are expected...
The Asia Pacific organoids market is expected to reach US$ 513.74 million in 2027 from US$ 97.02 million in 2019. The market is estimated to grow at a CAGR of 23.1% from 2020 to 2027. Rising adoption of biobanking and tumor modelling and alternatives for animal testing models acting as kingpins are expected to augment the growth of the...
The global human microbiome market is expected to reach US$ 1,873.53 million by 2027 from US$ 356.29 million in 2019. The market is estimated to grow with a CAGR of 23.6% from 2020 to 2027. The growth of the market is driven by the factors such as increasing incidence of lifestyle diseases, increasing focus on human microbiome therapies,...
On the rebound: Medicare reimbursement caps for physical therapy may constrain revenue growth Abstract Physical Therapists in the US Over the five years to 2019, the role of physical therapy in promoting health and wellness has increased, benefiting this industry. As the number of individuals aged...
Anatomic pathology market to register a CAGR of 7.1% from 2020 to 2025. The global anatomic pathology market size is projected to reach a value of USD 46.8 billion by 2025 from USD 33.3 billion in 2020, at a CAGR of 7.1% during the forecast period. The growth in this market is attributed to the high incidence of cancer...
Step by step: An aging US population and a rising prevalence of diabetes are expected to boost industry demand Abstract Podiatrists in the US Over the five years to 2019, the Podiatrists industry has stepped in the right direction. Revenue growth has been supported by the aging US population and the...
Market Overview
Cancer rates could further increase by 50%, to 15 million new cases, by 2020, as per the World Cancer Report. It also provides clear evidence that healthy lifestyles and public health action by governments and health practitioners can prevent as many as one-third of cancers, worldwide. The American Cancer...
The global interventional neuroradiology market is expected to reach US$ 3,254.55 Mn in 2027 from US$ 1,969.39 Mn in 2018. The market is estimated to grow with a CAGR of 5.9% from 2019-2027. Progressive aging population, increasing demand for minimally invasive procedures and rise in the prevalence of the cerebral aneurysm play vital role...
Pathology
World
APAC
Health Expenditure
Hospital Revenue
By continuing to use this site you consent to the use of cookies on your device as described in our Cookie Policy unless you have disabled them.
You can change your Cookie Settings at any time but parts of our site will not function correctly without them.